Actelion, being bought by J&J, says full year core net income rose 27 percent

Actelion, being bought by J&J, says full year core net income rose 27 percent


Swiss drugmaker Actelion's 2016 core net income rose 27 percent on accelerating sales of its newer medicines to treat deadly pulmonary arterial hypertension , it said on Tuesday. The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil, Switzerland January 26, 2017.



from Biotech News